Dexcom Inc
DXCM70.570USD
-0.810-1.13%
Horarios del mercado （ET）Cotizaciones retrasadas 15 min
27.57BCap. mercado
47.85P/E TTM
Más Datos de Dexcom Inc Compañía
DexCom, Inc. is a medical device company. The Company is primarily focused on the design, development, and commercialization of continuous glucose monitoring (CGM), systems for the management of diabetes and metabolic health by patients, caregivers, and clinicians. Its products include Dexcom G6, Dexcom G7, Stelo, Dexcom Share, and Dexcom ONE. The Company enables people to take control of health through innovative biosensing technology. Dexcom G6 is its integrated continuous glucose monitoring system (iCGM). Stelo is designed specifically for people with type II diabetes who do not use insulin as the first over-the-counter glucose biosensor in the United States. The Dexcom Share remote monitoring system, offered for use with any Dexcom system, uses an app on the patient’s compatible mobile device. Its Dexcom G7 is for adults and children (2+ years) living with type I or type II diabetes who are on any insulin or medications, at risk of hypoglycemia, and those with gestational diabetes.
Información de la empresa
Código de la empresaDXCM
Nombre de la empresaDexcom Inc
Fecha de salida a bolsaApr 14, 2005
Fundada en1999
Director ejecutivoMr. Kevin R. Sayer
Número de empleados10300
Tipo de seguridadOrdinary Share
Fin del año fiscalApr 14
Dirección6340 Sequence Dr
CiudadSAN DIEGO
Bolsa de valoresNASDAQ Global Select Consolidated
PaísUnited States of America
Código postal92121
Teléfono18582000200
Sitio Webhttps://www.dexcom.com/
Código de la empresaDXCM
Fecha de salida a bolsaApr 14, 2005
Fundada en1999
Ejecutivos de la empresa
Nombre
Nombre/Posición
Posición
Accionistas
Cambio
Dr. Eric J. Topol, M.D.
Dr. Eric J. Topol, M.D.
Independent Director
Independent Director
380.55K
+0.77%
Mr. Jacob Steven (Jake) Leach
Mr. Jacob Steven (Jake) Leach
Executive Vice President, Chief Operating Officer
Executive Vice President, Chief Operating Officer
276.26K
+6.52%
Mr. Kevin R. Sayer
Mr. Kevin R. Sayer
Chairperson of the Board, President, Chief Executive Officer
Chairperson of the Board, President, Chief Executive Officer
233.94K
+11.70%
Mr. Mark G. Foletta
Mr. Mark G. Foletta
Lead Independent Director
Lead Independent Director
59.37K
-4.34%
Mr. Steven R. (Steve) Altman
Mr. Steven R. (Steve) Altman
Independent Director
Independent Director
58.63K
+5.18%
Mr. Richard Alexander Collins
Mr. Richard Alexander Collins
Independent Director
Independent Director
41.94K
+7.44%
Mr. Jereme M. Sylvain
Mr. Jereme M. Sylvain
Chief Financial Officer, Executive Vice President
Chief Financial Officer, Executive Vice President
40.15K
+34.41%
Mr. Nicholas (Nick) Augustinos
Mr. Nicholas (Nick) Augustinos
Independent Director
Independent Director
39.70K
+8.30%
Ms. Bridgette P. Heller
Ms. Bridgette P. Heller
Independent Director
Independent Director
23.00K
-1.51%
Mr. Kyle Malady
Mr. Kyle Malady
Independent Director
Independent Director
18.14K
--
Ver más
Nombre
Nombre/Posición
Posición
Accionistas
Cambio
Dr. Eric J. Topol, M.D.
Dr. Eric J. Topol, M.D.
Independent Director
Independent Director
380.55K
+0.77%
Mr. Jacob Steven (Jake) Leach
Mr. Jacob Steven (Jake) Leach
Executive Vice President, Chief Operating Officer
Executive Vice President, Chief Operating Officer
276.26K
+6.52%
Mr. Kevin R. Sayer
Mr. Kevin R. Sayer
Chairperson of the Board, President, Chief Executive Officer
Chairperson of the Board, President, Chief Executive Officer
233.94K
+11.70%
Mr. Mark G. Foletta
Mr. Mark G. Foletta
Lead Independent Director
Lead Independent Director
59.37K
-4.34%
Mr. Steven R. (Steve) Altman
Mr. Steven R. (Steve) Altman
Independent Director
Independent Director
58.63K
+5.18%
Mr. Richard Alexander Collins
Mr. Richard Alexander Collins
Independent Director
Independent Director
41.94K
+7.44%
Desglose de ingresos
Divisa: USDHora de actualización: dom., 6 de abr
Divisa: USDHora de actualización: dom., 6 de abr
FY2024
FY2024Q4
FY2024Q3
FY2024Q2
FY2024Q1
FY2023
FY2023Q4
FY2023Q3
FY2023Q2
FY2023Q1
FY2022
FY2022Q4
FY2022Q3
FY2022Q2
FY2022Q1
FY2021
FY2020
FY2019
Por negocioUSD
Nombre
Ganancia
Proporción
Distributor
3.43B
85.05%
Direct
602.90M
14.95%
Por regiónUSD
Nombre
Ganancia
Proporción
United States
2.89B
71.65%
Outside of United states
1.14B
28.35%
Por negocio
Por región
Por negocioUSD
Nombre
Ganancia
Proporción
Distributor
3.43B
85.05%
Direct
602.90M
14.95%
Accionista
Hora de actualización: vie., 21 de feb
Hora de actualización: vie., 21 de feb
Estadísticas de accionistas
Tipo
Estadísticas de accionistas
Accionista
Proporción
The Vanguard Group, Inc.
11.82%
BlackRock Institutional Trust Company, N.A.
6.17%
State Street Global Advisors (US)
4.26%
Baillie Gifford & Co.
3.73%
Capital Research Global Investors
3.67%
Other
70.36%
Estadísticas de accionistas
Accionista
Proporción
The Vanguard Group, Inc.
11.82%
BlackRock Institutional Trust Company, N.A.
6.17%
State Street Global Advisors (US)
4.26%
Baillie Gifford & Co.
3.73%
Capital Research Global Investors
3.67%
Other
70.36%
Tipo
Accionista
Proporción
Investment Advisor
44.84%
Investment Advisor/Hedge Fund
35.69%
Hedge Fund
6.59%
Research Firm
3.56%
Pension Fund
2.27%
Bank and Trust
1.61%
Sovereign Wealth Fund
1.44%
Individual Investor
0.38%
Venture Capital
0.34%
Other
3.27%
Participación institucional
Hora de actualización: dom., 19 de ene
Hora de actualización: dom., 19 de ene
Periodo del informe
Número de instituciones
Acciones mantenidas
Proporción
Cambio
2025Q1
2198
383.01M
97.68%
-27.58M
2024Q4
2220
380.88M
97.47%
-26.96M
2024Q3
2145
382.31M
97.83%
-30.58M
2024Q2
2115
397.02M
99.11%
-4.31M
2024Q1
2093
389.18M
98.33%
-19.87M
2023Q4
2081
398.01M
103.26%
+83.33K
2023Q3
1994
389.89M
100.89%
-11.88M
2023Q2
1952
389.17M
100.78%
-12.73M
2023Q1
1908
390.83M
100.84%
-11.09M
2022Q4
1889
389.49M
100.81%
-14.66M
Ver más
Actividad de los accionistas
Nombre
Acciones mantenidas
Proporción
Cambio
Cambio %
Fecha
The Vanguard Group, Inc.
46.36M
11.82%
-900.98K
-1.91%
Dec 31, 2024
BlackRock Institutional Trust Company, N.A.
24.18M
6.17%
+3.21K
+0.01%
Dec 31, 2024
State Street Global Advisors (US)
16.69M
4.26%
+19.76K
+0.12%
Dec 31, 2024
Baillie Gifford & Co.
14.61M
3.73%
-404.87K
-2.70%
Dec 31, 2024
Capital Research Global Investors
14.37M
3.67%
-3.58M
-19.93%
Dec 31, 2024
Sands Capital Management, LLC
11.11M
2.83%
+790.30K
+7.66%
Dec 31, 2024
Geode Capital Management, L.L.C.
9.99M
2.55%
+56.09K
+0.56%
Dec 31, 2024
Invesco Capital Management (QQQ Trust)
8.08M
2.06%
+108.41K
+1.36%
Feb 28, 2025
Nuveen LLC
7.82M
2%
+61.83K
+0.80%
Dec 31, 2024
Jennison Associates LLC
7.64M
1.95%
+710.86K
+10.25%
Dec 31, 2024
Ver más
ETFs relacionados
Hora de actualización: dom., 6 de abr
Hora de actualización: dom., 6 de abr
Nombre
Proporción
First Trust Nasdaq Lux Digi Health Solutions ETF
9.74%
Simplify Market Neutral Equity Long/Short ETF
9%
Langar Global HealthTech ETF
6.72%
Global X Internet of Things ETF
4.93%
Touchstone Sands Capital US Select Growth ETF
4.63%
Harbor Health Care ETF
4.29%
Motley Fool Mid-Cap Growth ETF
3.88%
Fidelity Digital Health ETF
3.8%
Motley Fool Global Opportunities ETF
3.63%
Global X Telemedicine & Digital Health ETF
3.55%
Ver más
First Trust Nasdaq Lux Digi Health Solutions ETF
Proporción9.74%
Simplify Market Neutral Equity Long/Short ETF
Proporción9%
Langar Global HealthTech ETF
Proporción6.72%
Global X Internet of Things ETF
Proporción4.93%
Touchstone Sands Capital US Select Growth ETF
Proporción4.63%
Harbor Health Care ETF
Proporción4.29%
Motley Fool Mid-Cap Growth ETF
Proporción3.88%
Fidelity Digital Health ETF
Proporción3.8%
Motley Fool Global Opportunities ETF
Proporción3.63%
Global X Telemedicine & Digital Health ETF
Proporción3.55%
Dividendos
Un total de
0.00
USD se ha distribuido en dividendos durante los últimos 5 años.
Fecha
Dividendos
Fecha de registro
Fecha de pago
Fecha ex-dividendo
Sin datos
División de acciones
Fecha
Tipo
Relación
Mar 28, 2022
Split
1>4
Fecha
Tipo
Relación
Mar 28, 2022
Split
1>4